Multiple Myeloma

A CRL has been issued by the FDA to the biologics license application seeking approval of linvoseltamab to treat some patients with multiple myeloma.

Donna Catamero, ANP-BC, OCN, CCRC, discusses the importance of quickly identifying and managing adverse effects from CAR T-cell therapy in patients with multiple myeloma.

Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT.

Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.

Treatment with linvoseltamab provided durable efficacy for patients with relapsed/refractory multiple myeloma.

Bispecific antibodies like teclistamab offer “more potent” treatment than monoclonal antibodies for patients with relapsed or refractory multiple myeloma.

The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.

The panel provides clinical advice on caring for patients with multiple myeloma who are treated with talquetamab.

Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.

Experts explore strategies to effectively manage toxicities associated with talquetamab in the treatment of multiple myeloma.

Experts discuss best practices for educating patients with multiple myeloma on the adverse effects associated with talquetamab treatment.

This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

The panel discussed resources to equip nurses in educating patients with multiple myeloma about their treatment options.

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.

Patients with relapsed/refractory multiple myeloma who also had a lower tumor burden were more likely to derive deeper responses to idecabtagene vicleucel.

Rates of MRD negativity increased with daratumumab plus VRd in newly diagnosed, transplant-eligible multiple myeloma.

These data may support belantamab mafodotin, bortezomib, and dexamethasone as a new standard of care for patients with relapsed/refractory multiple myeloma.

Findings from this safety run-in cohort of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma will steer how randomization of the MajesTEC-7 trial will commence.

Talquetamab treatment was safe and efficacious for patients with relapsed or refractory multiple myeloma, including those with comorbidities and poor functional status.

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.

A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.